Historically, insulin resistance during pregnancy has been ascribed to increased production of placental hormones and cortisol. The purpose of this study was to test this hypothesis by correlating the longitudinal changes in insulin sensitivity during pregnancy with changes in placental hormones, cortisol, leptin, and tumor necrosis factor (TNF)-α. Insulin resistance was assessed in 15 women (5 with gestational diabetes mellitus [GDM] and 10 with normal glucose tolerance) using the euglycemic-hyperinsulinemic clamp procedure, before pregnancy (pregravid) and during early (12–14 weeks) and late (34–36 weeks) gestation. Body composition, plasma TNF-α, leptin, cortisol, and reproductive hormones (human chorionic gonadotropin, estradiol, progesterone, human placental lactogen, and prolactin) were measured in conjunction with the clamps. Placental TNF-α was measured in vitro using dually perfused human placental cotyledon from five additional subjects. Compared with pregravid, insulin resistance was evident during late pregnancy in all women (12.4 ± 1.2 vs. 8.1 ± 0.8 10−2 mg · kg−1 fat-free mass · min−1 · μU−1 · ml−1). TNF-α, leptin, cortisol, all reproductive hormones, and fat mass were increased in late pregnancy (P < 0.001). In vitro, most of the placental TNF-α (94%) was released into the maternal circulation; 6% was released to the fetal side. During late pregnancy, TNF-α was inversely correlated with insulin sensitivity (r = −0.69, P < 0.006). Furthermore, among all of the hormonal changes measured in this study, the change in TNF-α from pregravid to late pregnancy was the only significant predictor of the change in insulin sensitivity (r = −0.60, P < 0.02). The placental reproductive hormones and cortisol did not correlate with insulin sensitivity in late pregnancy. Multivariate stepwise regression analysis revealed that TNF-α was the most significant independent predictor of insulin sensitivity (r = −0.67, P < 0.0001), even after adjustment for fat mass by covariance (r = 0.46, P < 0.01). These observations challenge the view that the classical reproductive hormones are the primary mediators of change in insulin sensitivity during gestation and provide the basis for including TNF-α in a new paradigm to explain insulin resistance in pregnancy.

Pregnancy is a period marked by profound changes in a woman’s hormonal status and metabolism. The ability to regulate nutrient balance during this period is critical to the health of the mother and the growing fetus. Insulin is one of the key regulators of metabolism, and significant changes in insulin sensitivity and its ability to control glucose, fat, and protein during pregnancy have been well documented (14). Previous reports have also shown that maternal insulin resistance plays an important role in the regulation of maternal energy metabolism, fat accretion, and fetal growth (5,6). In gestational diabetes mellitus (GDM), greater insulin resistance may lead to abnormal blood glucose and fetal macrosomia, may increase the likelihood of obstetric complications, and in some cases, may increase the risk of stillbirth. The cellular mediators of insulin resistance in late pregnancy have long been ascribed to alterations in cortisol and placental-derived hormones including human placental lactogen (HPL), progesterone, and estrogen (79). To our knowledge, however, the changes in insulin sensitivity during gestation have not yet been correlated with hormonal changes using a prospective longitudinal design.

Recently, investigators have focused on several new potential mediators of insulin resistance including the cytokine tumor necrosis factor (TNF)-α, the anti-obesity hormone leptin, and adipose-derived resistin, adiponectin, and free fatty acids (10,11). Among these candidates, TNF-α and leptin are known to be produced in the placenta and therefore could play a central role in insulin resistance during pregnancy (1214). Although increased circulating TNF-α levels have been associated with insulin resistance in obesity, aging, sepsis, muscle damage, and preeclamptic pregnancy, reports of change in levels during normal pregnancy and GDM are equivocal (1522). Furthermore, because TNF-α is synthesized and secreted from the placenta and adipose tissue, the origin of circulating levels during pregnancy remains largely unknown. Leptin was first identified as a product of the ob gene in adipose tissue and is thought to regulate energy balance through central hypothalamic pathways, but it may also play a role in insulin resistance by promoting lipid oxidation and inhibiting lipid synthesis (2325). There are several reports of increased circulating leptin during pregnancy, due in part to placental secretion (13,14,26).

The primary purpose of this prospective study was to relate the longitudinal changes in concentrations of reproductive hormones (HPL, progesterone, human chorionic gonadotropin [hCG], prolactin, and estradiol), TNF-α, leptin, and cortisol with the corresponding changes in maternal insulin sensitivity as measured by the euglycemic-hyperinsulinemic clamp. To further elucidate the role of TNF-α as a mediator of maternal insulin resistance, we examined the placenta as a potential contributing source of maternal circulating TNF-α using the dual perfusion model of human placental cotyledon.

Subjects.

Fifteen women (10 with normal glucose tolerance [NGT] and 5 who developed GDM) volunteered to participate in the longitudinal evaluation of insulin sensitivity during pregnancy (Table 1). These subjects are a subset of a larger study examining insulin sensitivity (5,27). Euglycemic-hyperinsulinemic clamps, fasting blood samples, and body composition measurements were performed on each subject, on three occasions: pregravid and during both early (12–14 weeks) and late (34–36 weeks) pregnancy. The women with GDM had abnormal glucose tolerance during the third trimester according to the criteria of Carpenter and Coustan (28). The protocol was approved by the Institutional Review Board for Human Subjects, and all volunteers signed an informed consent form in accordance with the MetroHealth Medical Center guidelines for the protection of human subjects.

Body composition.

Body composition was determined by hydrostatic weighing and total body water using a two-compartment model according to the method described by Catalano et al. (29). Height was measured without shoes to the nearest 1.0 cm, and body weight was measured to the nearest 0.1 kg.

Euglycemic-hyperinsulinemic clamps.

Single-stage euglycemic-hyperinsulinemic clamps were performed as described previously (30,31). Endogenous glucose output was measured using a primed constant infusion of [6,6-2H2] glucose. Hyperinsulinemia was achieved using a primed-continuous infusion (40 mU · m−2 · min−1) of human insulin (Humulin; Eli Lilly, Indianapolis, IN) for a period of 2 h. Plasma glucose levels were clamped at 5.0 mmol/l using a variable glucose infusion (20% dextrose). Blood samples for plasma glucose and insulin determination were drawn at 5- and 10-min intervals, respectively, during the clamp.

Placental perfusions.

Five human placentas from uncomplicated pregnancies were collected immediately after cesarean sections. Perfusion of a suitable placental lobule was carried out as described previously (32). The placenta was washed before perfusion, and the medium was recirculated in the fetal and maternal circulation for 120 min. The media on both circuits were continuously gassed with 95% O2, 5% CO2. The volumes of fetal (Vf) and maternal (Vm) perfusion media collected at the end of the washing and recirculation period were recorded, and the media were stored at −20°C for later analysis. To estimate TNF-α release into the fetal (Qf = Cf × Vf) and maternal (Qm = Cm × Vm) circulation, TNF-α concentrations were measured in fetal (Cf) and maternal (Cm) media. These values were divided by the duration of the perfusion (t = 120 min) to give the rates of TNF-α release toward the fetal and maternal side of the placental circulation. TNF-α was also assessed on triplicate tissue samples in the placenta, before (Qti), and at the end of (Qte) the perfusion to evaluate changes in placental TNF-α (Q = Qte − Qti). The rate of placental TNF-α synthesis was estimated as PLS = Qf + Qm + Q divided by the duration of the perfusion for one cotyledon, and as TPS = PLS × P/l, where P/l is the placenta/lobule weight ratio, for the whole placenta.

Analytical procedures.

All samples for TNF-α, leptin, cortisol, and the reproductive hormones were run in duplicate in a single assay. Plasma TNF-α concentrations were measured by enzyme-linked immunosorbent assay (Quantikine HS; R&D Systems, Minneapolis, MN). The intra-assay coefficient of variation was 14%, the minimum detectable limit of the assay was 0.18 pg/ml, and the lowest standard was 0.5 pg/ml. Plasma glucose concentrations were measured by the glucose oxidase method (Yellow Springs Instruments, Yellow Springs, OH). Blood samples for insulin measurements were centrifuged at 4°C, and the plasma was stored at −70°C for subsequent analysis by a double-antibody radioimmunoassay (RIA) as previously described (27). Plasma cortisol, estradiol, HPL, and progesterone were determined by RIA (Diagnostic Products, Los Angeles, CA). Plasma leptin samples were also measured by RIA (Linco Research, St. Charles, MO). Plasma hCG was determined by immunoradiometric assay (Diagnostic Products). Plasma prolactin was measured by RIA (Nichols Institute Diagnostics, San Juan Capistrano, CA)

The [6,6-2H2]glucose in the plasma samples was isolated by ion-exchange chromatography. A penta-acetate derivative of glucose was prepared according to Tserng and Kalhan (33). Plasma enrichment was determined using a gas chromatograph mass spectrometer (model 5985B; Hewlett-Packard, Palo Alto, CA).

Calculations and statistical analysis.

The insulin sensitivity index from the clamp procedure was estimated as the glucose infusion rate plus endogenous glucose output divided by the mean insulin concentration during the clamp and is expressed as 10−2 milligrams per kilogram fat-free mass (FFM) per minute per microunit per milliliter (10−2 mg · kg−1 FFM · min−1/μU · ml−1).

All values are presented as means ± SE. Differences between dependent variables were examined with two-way ANOVA. Specific mean differences were identified with a Scheffe post-hoc test. The relationship between insulin sensitivity measured during the clamp and estimated from the various equations was based on univariate and multivariate correlation analysis. The data were analyzed using the Statview II statistical package (Abacus Concepts, Berkeley, CA). The α level for statistical significance was set at 0.05.

Body weight and body composition responses.

Mean age at entry into the study was 31 ± 1 years, and parity was 0.93 ± 0.15. Body weight pregravid was 71.2 ± 5.0 kg and did not change markedly during early pregnancy (72.7 ± 5.0 kg) but, as expected, increased during late pregnancy (83.0 ± 5.1 kg). Fat mass was similar pregravid (25.7 ± 3.7 kg) and during early pregnancy (25.4 ± 3.3 kg) and increased during late pregnancy (28.3 ± 3.4 kg; P < 0.0003).

Insulin action.

Pregravid, there was no difference in insulin sensitivity between the lean and obese women with NGT, but women who developed GDM were more insulin resistant than those with NGT (Table 2). During early pregnancy, insulin sensitivity increased slightly in all subgroups of women, and when the data were combined, there was a ∼ 14% increase in sensitivity (Fig. 1). However, by late pregnancy, insulin sensitivity was reduced ∼65% versus pregravid. All subgroups of women had similar relative changes in sensitivity regardless of whether they had NGT or GDM. Fasting glucose measurements declined during early and late pregnancy (P < 0.05) versus pregravid. In contrast, fasting insulin was significantly increased (P < 0.05) in late pregnancy compared with either pregravid or early pregnancy.

TNF-α and hormonal responses.

The women showed a downward trend (13%) in TNF-α from pregravid (1.79 ± 0.27 pg/ml) to early pregnancy (1.56 ± 0.22 pg/ml) and a 45% increase in late pregnancy (2.59 ± 0.24 pg/ml; P < 0.004) (Fig. 2). These changes were consistent regardless of NGT or GDM status (Table 3). During late pregnancy, TNF-α levels were higher (P < 0.01) for women with GDM than for lean women with NGT.

Data obtained from the in vitro experiments showed that the rate of placental TNF-α production was 123.1 ± 51.6 pg · min−1 · g−1 placenta. Accumulation in the placental tissue during the course of perfusion was high (2,316 ± 1,671 pg/min) compared with fetal and maternal release (15.6 ± 4.9 pg/min and 493.2 ± 205.8 pg/min, respectively). Most of the TNF-α released in the medium (94 ± 3%) was delivered into the maternal circulation; 6 ± 3% was released into the fetal circulation.

In a univariate analysis, TNF-α was significantly correlated with insulin sensitivity pregravid (r = −0.54, P < 0.03) and during early (r = −0.68, P < 0.003) and late (r = −0.58, P < 0.02) pregnancy (Fig. 3). Plasma TNF-α data for one of the obese NGT subjects was >2 SDs from the mean; when these data were taken out of the analysis, the correlation between TNF-α and insulin sensitivity in late pregnancy improved to r = −0.69 and P < 0.006. Further, the change in TNF-α from pregravid to late pregnancy was inversely related to the corresponding change in insulin sensitivity (Fig. 4). Using a stepwise regression analysis model, TNF-α was found to be a primary predictor of insulin sensitivity in pregnant women and explained >45% of the variance in the model (Table 4). Because plasma TNF-α was correlated with fat mass (r = 0.68, P < 0.01 in late pregnancy), the regression model was adjusted for body fat. After this adjustment, the strength of the correlation was reduced, but TNF-α remained the best predictor of insulin sensitivity (r = 0.46, P < 0.01).

As expected, circulating leptin levels increased from pregravid (21.2 ± 4.9 ng/ml) to early pregnancy (31.5 ± 6.5 ng/ml) and remained elevated through late pregnancy (32.1 ± 6.8 ng/ml). Leptin levels were lower in lean women with NGT than in obese women with GDM (Table 3). In univariate analysis, there was an inverse correlation between leptin and insulin sensitivity (r = −0.58, P < 0.01), but when fat mass was entered as a covariate, the correlation was no longer significant (r = 0.02). In the stepwise regression analysis, leptin, unadjusted for fat mass, was the second best predictor of insulin sensitivity, contributing an additional 9% to the model (Table 4). Plasma cortisol also increased from pregravid (10.9 ± 1.0 μg/dl) to early pregnancy (16.6 ± 1.3 μg/dl) and increased further in late pregnancy (32.3 ± 2.2 μg/dl). The correlation between cortisol and insulin sensitivity was significant (r = −0.34, P < 0.05). Cortisol entered the insulin sensitivity stepwise regression model at the third step and contributed an additional 7% to the variance.

Plasma estradiol, progesterone, and prolactin were all elevated during early pregnancy and increased further during late pregnancy (Table 5). Plasma HPL was significantly elevated and hCG was reduced in late compared with early pregnancy. Notably, there were no significant correlations between these hormones and insulin sensitivity in late pregnancy (hCG, r = −0.29, P = 0.31; HPL, r = −0.24, P = 0.39; prolactin, r = −0.13, P = 0.67; estradiol, r = −0.12, P = 0.68; and progesterone, r = −0.10, P = 0.72).

Historically, placental hormones are considered the primary mediators of insulin resistance during gestation (79). To our knowledge, however, there are no studies in the literature that have directly examined the relationship between these hormones and insulin sensitivity throughout human pregnancy. Herein, we report for the first time that among women with NGT and GDM, TNF-α is a significant predictor of insulin resistance during pregnancy. Together with a small additive contribution from leptin and cortisol, TNF-α exerted a significant influence on insulin-mediated glucose disposal, whereas the contribution of HPL, hCG, estradiol, progesterone, and prolactin to insulin resistance was not significant. This observation challenges the long-held axiom that pregnancy-related insulin resistance is due to the production of placental reproductive hormones.

Subjects in the present study had a broad range of insulin sensitivity and body composition before pregnancy. Pregravid, 10 of the women had NGT and 5 had a high normal response; the latter 5 subsequently developed GDM during pregnancy. Differences in pregravid glucose metabolism were also evident in clamp-derived insulin sensitivity measures. Based on body composition measures, 5 of the 10 women with NGT were lean and 5 were obese, whereas all 5 of the women with GDM were obese. However, irrespective of these differences, changes in insulin sensitivity during pregnancy were similar for all women. Because the relative changes in insulin sensitivity were similar for lean and obese women with NGT and GDM, the data for the groups was combined to identify predictors of change in insulin sensitivity during pregnancy.

Circulating TNF-α showed a downward trend during early pregnancy and increased during the third trimester, thus mirroring insulin sensitivity changes during those periods. This observation is consistent with previous studies showing an increase in plasma TNF-α in late pregnancy (19,21) and demonstrates that when the same women are followed longitudinally, significant changes in TNF-α can be detected. Although reproductive hormones are increased 5- to 30-fold, they have relatively little predictive power, despite the fact that they have been traditionally associated with insulin resistance during pregnancy (79). Two other potential mediators of insulin resistance, leptin and cortisol, also correlated inversely with changes in insulin sensitivity in late pregnancy, but to a far lesser degree. Because TNF-α and leptin are secreted from fat cells as well as the placenta (13,14,23, 34), we adjusted the data to account for changes in maternal fat accretion during the pregnancy period. When the data were analyzed with fat mass as a covariate, TNF-α remained a significant predictor of insulin sensitivity, whereas leptin was no longer significant. Thus, despite the increase in fat mass during gestation and the difference in body fat between lean women with NGT and obese women with NGT or GDM, plasma TNF-α was an independent correlate of insulin sensitivity during pregnancy.

The placenta is an important source of TNF-α in human pregnancy, with the greatest production rates evident in late gestation (12). We previously observed that, similar to leptin, increased TNF-α levels in pregnancy fall rapidly after delivery (35), consistent with the idea that the increase in circulating TNF-α during late pregnancy is due to placental secretion. Our in vitro model suggests that the vast majority of the TNF-α synthesized by the placenta is delivered to the maternal side, with relatively little going into fetal circulation. Thus, TNF-α appears to be secreted asymmetrically into the maternal circulation in a manner similar to leptin (14). These findings may also help to explain the rapid reversal of insulin resistance after delivery, since maternal levels of TNF-α and leptin decrease substantially after delivery of the placenta.

Using an in vitro tissue explant incubation model, it has been shown that placentas from women with GDM release greater amounts of TNF-α in response to a glucose stimulus than those from women with NGT (36). Whether increased placental TNF-α production may explain increased insulin resistance in GDM compared with NGT is not clear; however, our data confirm a previous report that plasma TNF-α levels are higher in late gestation among women with GDM than in lean women with NGT (37). Because women with GDM were controlled with diet and had similar baseline glucose levels compared with obese pregnant women with NGT, the levels of TNF-α were not different. However, given that TNF-α may predict insulin resistance during late gestation, it could also contribute to greater insulin resistance in uncontrolled GDM subjects.

A number of studies have described a direct role for TNF-α in the pathophysiology of insulin resistance. In vitro studies have shown that TNF-α downregulates insulin receptor signaling in cultured adipocytes (38), hepatocytes (39), and skeletal muscle (40). Furthermore, increased TNF-α is associated with insulin resistance in a broad range of conditions including obesity (16), aging (17), sepsis (18), and after muscle damage (15). TNF-α activates a pathway that increases sphingomyelinase and ceramides and appears to interfere with insulin receptor autophosphorylation. Recently, it has been shown that TNF-α promotes serine phosphorylation of insulin receptor substrate (IRS)-1, thus impairing its association with the insulin receptor (41). In pregnancy, there is evidence that insulin receptor and IRS-1 tyrosine phosphorylation are impaired, and serine phosphorylation is increased in late gestation in skeletal muscle (42,43). Therefore, it seems plausible that elevated levels of TNF-α in late gestation could attenuate insulin signaling, thus causing the decreased insulin sensitivity observed in pregnancy. Preliminary data from our laboratory suggest that insulin receptor and IRS-1 changes in skeletal muscle are reversible after pregnancy, indicating that TNF-α may be an important hormonal mediator responsible for insulin resistance in human pregnancy (J.P.K., P.M.C., unpublished observations).

Maternal circulating leptin increases during pregnancy, with most of the increase occurring in the first trimester (26). Whereas the placenta appears to be a primary site of maternal leptin production (14), secretion from the fat cell is also important, and plasma leptin is positively correlated with level of obesity (44). In the present study, leptin was increased in all women in early pregnancy, remained elevated in late pregnancy, and was highest in the more obese GDM group. To adjust for the possible confounding effect of obesity and increased fat mass on the relationship between leptin and insulin sensitivity, we covaried for body fat and found that the correlation was no longer significant. Because the increased leptin per se was not predictive of insulin sensitivity, one interpretation is that in addition to insulin resistance, leptin resistance may also develop in late pregnancy.

Data from the present study indicate that reproductive hormones and cortisol do not significantly correlate with the change in insulin sensitivity during pregnancy. Because these hormones have established diabetogenic properties, possibly acting through lipolytic mechanisms (8,45), one would expect to see some association with the insulin resistance that was present at this time. These data suggest that whereas the placental hormones and cortisol have specific functions in the mother and feto-placental unit, their association with maternal insulin sensitivity is limited (placental growth hormone notwithstanding). However, this does not preclude the possibility that these hormones can play a permissive role in insulin resistance in pregnancy by potentiating the effects of more direct mediators such as TNF-α. Alternatively, these hormones could have an effect on other non- placental-derived mediators of insulin sensitivity such as free fatty acids, resistin, or adiponectin.

In conclusion, insulin resistance during late gestation is significantly correlated with changes in circulating TNF-α, irrespective of fat mass. The primary source of the increased TNF-α appears to be the placenta. Studies in vitro have shown that TNF-α inhibits insulin signaling and insulin-regulated glucose uptake, thus suggesting that the insulin resistance of pregnancy may be mediated through this cytokine. These observations provide an alternative to the placental-derived reproductive hormone paradigm to explain insulin resistance during pregnancy. The regulation of TNF-α may provide an important target for physiological interventions designed to reduce the risk of adverse pregnancy outcomes related to insulin resistance.

FIG. 1.

Insulin sensitivity measured during euglycemic-hyperinsulinemic clamps performed pregravid and during early (12–14 weeks) and late (34–36 weeks) pregnancy. Data are means ± SE; n = 15. Glucose disposal rates and insulin concentrations were calculated for the final 150–180 min of the clamp. Units are expressed relative to FFM. *Significantly increased from pregravid, P < 0.02. †Significantly decreased from pregravid, P < 0.0001.

FIG. 1.

Insulin sensitivity measured during euglycemic-hyperinsulinemic clamps performed pregravid and during early (12–14 weeks) and late (34–36 weeks) pregnancy. Data are means ± SE; n = 15. Glucose disposal rates and insulin concentrations were calculated for the final 150–180 min of the clamp. Units are expressed relative to FFM. *Significantly increased from pregravid, P < 0.02. †Significantly decreased from pregravid, P < 0.0001.

Close modal
FIG. 2.

Plasma TNF-α concentrations for all women pregravid and during early (12–14 weeks) and late (34–36 weeks) pregnancy. Data are mean ± SE; n = 15. Fasting blood samples were collected before each corresponding clamp. *Significantly higher than pregravid, P < 0.004.

FIG. 2.

Plasma TNF-α concentrations for all women pregravid and during early (12–14 weeks) and late (34–36 weeks) pregnancy. Data are mean ± SE; n = 15. Fasting blood samples were collected before each corresponding clamp. *Significantly higher than pregravid, P < 0.004.

Close modal
FIG. 3.

Correlation between TNF-α and insulin sensitivity in late pregnancy (r = −0.58, P < 0.02). Data are shown for five lean women with NGT (), five obese women with NGT (⧫), and five obese women with GDM (). The correlation and regression equation based on data excluding one subject who was an outlier was r = −0.69, P < 0.006; y = − 4.242x + 18.426 (see results).

FIG. 3.

Correlation between TNF-α and insulin sensitivity in late pregnancy (r = −0.58, P < 0.02). Data are shown for five lean women with NGT (), five obese women with NGT (⧫), and five obese women with GDM (). The correlation and regression equation based on data excluding one subject who was an outlier was r = −0.69, P < 0.006; y = − 4.242x + 18.426 (see results).

Close modal
FIG. 4.

Correlation between the change in TNF-α and the change in insulin sensitivity from pregravid to late pregnancy (r = −0.60, P < 0.02). Data are shown for five lean women with NGT (), five obese women with NGT (⧫), and five obese women with GDM ().

FIG. 4.

Correlation between the change in TNF-α and the change in insulin sensitivity from pregravid to late pregnancy (r = −0.60, P < 0.02). Data are shown for five lean women with NGT (), five obese women with NGT (⧫), and five obese women with GDM ().

Close modal
TABLE 1

Subject characteristics and glucose tolerance pregravid and during late pregnancy

Lean NGTObese NGTGDM
Age (years) 33 ± 2 30 ± 1 29 ± 2 
Parity 1.2 ± 0.4 0.8 ± 0.2 1.0 ± 0.3 
Weight (kg) 53.5 ± 1.4 76.8 ± 7.4* 83.3 ± 9.4* 
BMI (kg/m219.8 ± 1.0 27.3 ± 2.4* 30.8 ± 2.8* 
Body fat (%) 25.0 ± 1.6 36.6 ± 3.2* 40.1 ± 3.2* 
2-h Glucose, pregravid 102.6 ± 17.8 106.6 ± 2.8 141.0 ± 6.5 
2-h Glucose, during late pregnancy 125.0 ± 8.3 145.6 ± 8.1 173.4 ± 4.9* 
Lean NGTObese NGTGDM
Age (years) 33 ± 2 30 ± 1 29 ± 2 
Parity 1.2 ± 0.4 0.8 ± 0.2 1.0 ± 0.3 
Weight (kg) 53.5 ± 1.4 76.8 ± 7.4* 83.3 ± 9.4* 
BMI (kg/m219.8 ± 1.0 27.3 ± 2.4* 30.8 ± 2.8* 
Body fat (%) 25.0 ± 1.6 36.6 ± 3.2* 40.1 ± 3.2* 
2-h Glucose, pregravid 102.6 ± 17.8 106.6 ± 2.8 141.0 ± 6.5 
2-h Glucose, during late pregnancy 125.0 ± 8.3 145.6 ± 8.1 173.4 ± 4.9* 

Data are means ± SE; n = 5 per group.

*

Significantly different from lean NGT group, P < 0.02.

Significantly different from pregravid, P < 0.03.

TABLE 2

Glucose and insulin metabolism measured using euglycemic-hyperinsulinemic clamps and fasting glucose and insulin levels in women pregravid and during both early and late pregnancy

PregravidEarly pregnancyLate pregnancy
ISCLAMP (10−2 mg · kg−1 FFM · min−1/μU · ml−1   
 Lean NGT 14.3 ± 1.3 17.4 ± 1.2 9.9 ± 0.5* 
 Obese NGT 14.2 ± 1.9 15.4 ± 3.1 9.5 ± 1.5* 
 Obese GDM 8.8 ± 2.5 9.8 ± 2.0 4.9 ± 0.8* 
Fasting glucose (mg/dl)    
 Lean NGT 90.4 ± 2.0 83.6 ± 1.2* 81.0 ± 0.9* 
 Obese NGT 93.2 ± 1.7 86.8 ± 1.8 81.0 ± 1.9* 
 Obese GDM 98.0 ± 1.8 87.4 ± 2.9 88.6 ± 4.5* 
Fasting insulin (μU/ml)    
 Lean NGT 8.2 ± 0.9 6.1 ± 0.6 10.7 ± 0.9* 
 Obese NGT 9.0 ± 1.6 9.2 ± 3.0 11.9 ± 2.7* 
 Obese GDM 18.9 ± 4.1 16.8 ± 5.8 27.5 ± 5.6* 
PregravidEarly pregnancyLate pregnancy
ISCLAMP (10−2 mg · kg−1 FFM · min−1/μU · ml−1   
 Lean NGT 14.3 ± 1.3 17.4 ± 1.2 9.9 ± 0.5* 
 Obese NGT 14.2 ± 1.9 15.4 ± 3.1 9.5 ± 1.5* 
 Obese GDM 8.8 ± 2.5 9.8 ± 2.0 4.9 ± 0.8* 
Fasting glucose (mg/dl)    
 Lean NGT 90.4 ± 2.0 83.6 ± 1.2* 81.0 ± 0.9* 
 Obese NGT 93.2 ± 1.7 86.8 ± 1.8 81.0 ± 1.9* 
 Obese GDM 98.0 ± 1.8 87.4 ± 2.9 88.6 ± 4.5* 
Fasting insulin (μU/ml)    
 Lean NGT 8.2 ± 0.9 6.1 ± 0.6 10.7 ± 0.9* 
 Obese NGT 9.0 ± 1.6 9.2 ± 3.0 11.9 ± 2.7* 
 Obese GDM 18.9 ± 4.1 16.8 ± 5.8 27.5 ± 5.6* 

Data are means ± SE; n = 5 per group. IS, insulin sensitivity derived from euglycemic-hyperinsulinemic clamp studies.

*

Significantly different from pregravid, P < 0.001.

Significantly different from lean NGT group, P < 0.05.

TABLE 3

Longitudinal changes in TNF-α, leptin, and cortisol in women pregravid and during both early and late pregnancy

PregravidEarly pregnancyLate pregnancy
TNF-α (pg/ml)    
 Lean NGT 1.58 ± 0.32 1.28 ± 0.11 2.13 ± 0.11* 
 Obese NGT 2.05 ± 0.66 1.70 ± 0.65 2.80 ± 0.72 
 Obese GDM 1.75 ± 0.43 1.69 ± 0.29 2.84 ± 0.17* 
Leptin (ng/ml)    
 Lean NGT 7.9 ± 1.4 8.9 ± 0.8 11.6 ± 1.6 
 Obese NGT 23.1 ± 9.4 39.2 ± 13.5 36.4 ± 12.0 
 Obese GDM 31.0 ± 8.2 42.4 ± 7.0 44.1 ± 12.2 
Cortisol (μg/dl)    
 Lean NGT 13.8 ± 1.4 17.3 ± 1.9 32.3 ± 2.2* 
 Obese NGT 8.7 ± 1.2 15.5 ± 2.2* 30.0 ± 3.9* 
 Obese GDM 10.3 ± 1.6 17.0 ± 3.2* 32.1 ± 4.2* 
PregravidEarly pregnancyLate pregnancy
TNF-α (pg/ml)    
 Lean NGT 1.58 ± 0.32 1.28 ± 0.11 2.13 ± 0.11* 
 Obese NGT 2.05 ± 0.66 1.70 ± 0.65 2.80 ± 0.72 
 Obese GDM 1.75 ± 0.43 1.69 ± 0.29 2.84 ± 0.17* 
Leptin (ng/ml)    
 Lean NGT 7.9 ± 1.4 8.9 ± 0.8 11.6 ± 1.6 
 Obese NGT 23.1 ± 9.4 39.2 ± 13.5 36.4 ± 12.0 
 Obese GDM 31.0 ± 8.2 42.4 ± 7.0 44.1 ± 12.2 
Cortisol (μg/dl)    
 Lean NGT 13.8 ± 1.4 17.3 ± 1.9 32.3 ± 2.2* 
 Obese NGT 8.7 ± 1.2 15.5 ± 2.2* 30.0 ± 3.9* 
 Obese GDM 10.3 ± 1.6 17.0 ± 3.2* 32.1 ± 4.2* 

Data are means ± SE; n = 5 per group.

*

Significantly different from pregravid, P < 0.01.

Significantly different from lean NGT group, P < 0.02.

TABLE 4

Stepwise logistic regression: factors correlated with insulin sensitivity for the combined time periods

r2Δr2P
Insulin sensitivity    
 TNF-α (pg/ml) 0.453 — 0.0001 
 Leptin (ng/ml) 0.546 0.093 0.0001 
 Cortisol (μg/dl) 0.616 0.070 0.0001 
 hCG (mIU/ml) 0.685 0.069 0.0001 
r2Δr2P
Insulin sensitivity    
 TNF-α (pg/ml) 0.453 — 0.0001 
 Leptin (ng/ml) 0.546 0.093 0.0001 
 Cortisol (μg/dl) 0.616 0.070 0.0001 
 hCG (mIU/ml) 0.685 0.069 0.0001 
TABLE 5

Longitudinal change in reproductive hormones in women pregravid and during both early and late pregnancy

PregravidEarly pregnancyLate pregnancy
hCG (IU/ml) NA 42.4 ± 4.6 19.4 ± 4.0* 
Estradiol (pg/ml) 132.6 ± 26.7 1814.5 ± 189.3 11598.2 ± 863.5* 
Progesterone (ng/ml) 2.3 ± 0.9 31.5 ± 2.1 137.5 ± 14.2* 
HPL (μg/ml) NA 0.9 ± 0.1 7.8 ± 0.5* 
Prolactin (ng/ml) 10.6 ± 1.1 28.8 ± 1.8 151.2 ± 8.8* 
PregravidEarly pregnancyLate pregnancy
hCG (IU/ml) NA 42.4 ± 4.6 19.4 ± 4.0* 
Estradiol (pg/ml) 132.6 ± 26.7 1814.5 ± 189.3 11598.2 ± 863.5* 
Progesterone (ng/ml) 2.3 ± 0.9 31.5 ± 2.1 137.5 ± 14.2* 
HPL (μg/ml) NA 0.9 ± 0.1 7.8 ± 0.5* 
Prolactin (ng/ml) 10.6 ± 1.1 28.8 ± 1.8 151.2 ± 8.8* 

Data are means ± SE; n = 15.

Significantly different from pregravid, P < 0.01.

*

Significantly different from early pregnancy, P < .01.

This research was supported by National Institutes of Health Grant HD-11089 and HD-22965 (to P.M.C.) and General Clinical Research Center grant MO1-RR-080.

The authors thank the research volunteers for their cooperation and compliance with the project.

1.
Freinkel N, Metzger BE, Nitzan M, Daniel R, Surmaczynska BZ, Nagel TC: Facilitated anabolism in late pregnancy: some novel maternal compensations for accelerated starvation. Paper presented at the Eighth Congress of the International Diabetes Foundation, Brussels,
1973
2.
Phelps RL, Metzger BE, Freinkel N: Carbohydrate metabolism in pregnancy. XVII. Diurnal profiles of plasma glucose, insulin, free fatty acids, triglycerides, cholesterol, and individual amino acids in late normal pregnancy.
Am J Obstet Gynecol
140
:
730
–736,
1981
3.
Metzger BE, Phelps RL, Freinkel N, Navickas IA: Effects of gestational diabetes on diurnal profiles of plasma glucose, lipids, and individual amino acids.
Diabetes Care
3
:
402
–409,
1980
4.
Ryan EA, O’Sullivan MJ, Skylar JS: Insulin action during pregnancy: studies with the euglycemic clamp technique.
Diabetes
34
:
380
–389,
1985
5.
Catalano PM, Roman-Drago NM, Amini SB, Sims EAH: Longitudinal changes in body composition and energy balance in lean women with normal and abnormal glucose tolerance during pregnancy.
Am J Obstet Gynecol
179
:
156
–165,
1998
6.
Catalano PM, Drago NM, Amini SB: Maternal carbohydrate metabolism and its relationship to fetal growth and body composition.
Am J Obstet Gynecol
172
:
1464
–1470,
1995
7.
Ryan EA, Enns L: Role of gestational hormones in the induction of insulin resistance.
J Clin Endocrin Metabol
67
:
341
–347,
1988
8.
Kalkhoff RK, Kissebah AH, Kim H-J: Carbohydrate and lipid metabolism during normal pregnancy: relationship to gestational hormone action. In
The Diabetic Pregnancy: A Perinatal Perspective
. Merkatz IR, Adam PAJ, Eds. New York, Grune & Straton,
1979
, p.
3
–21
9.
Barbieri RL: Endocrine disorders in pregnancy. In
Reproductive Endocrinology
, 4th ed. Yen SSC, Jaffe RB, Barbieri RL, Eds. Philadelphia, W.B. Saunders,
1999
10.
Smith U, Axelsen M, Carvalho E, Eliasson B, Jansson PA, Wesslau C: Insulin signaling and action in fat cells: associations with insulin resistance and type 2 diabetes.
Ann N Y Acad Sci
18
:
119
–126,
1999
11.
Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin.
Curr Opin Lipidol
13
:
51
–59,
2002
12.
Chen H, Yang Y, Hu X, Yelavarthi K, Fishback J, Hunt J: Tumor necrosis factor alpha mRNA and protein are present in human placental and uterine cells at early and late stages of gestation.
Am J Pathol
139
:
327
–335,
1991
13.
Masuzaki H, Ogawa Y, Sagawa N, Hosoda K, Matsumoto T, Mise H, Nishimura H, Yoshimasa Y, Tanaka I, Mori T, Nakao K: Nonadipose tissue production of leptin: leptin as a novel placenta-derived hormone in humans.
Nat Med
3
:
1029
–1033,
1997
14.
Lepercq J, Challier JC, Guerre-Millo M, Cauzac M, Vidal H, Haugel-de Mouzon S: Prenatal leptin production: evidence that fetal adipose tissue produces leptin.
J Clin Endocrin Metabol
86
:
2409
–2413,
2001
15.
del Aguila LF, Krishnan RK, Ulbrecht JS, Farrell PA, Correll PH, Lang CH, Zierath JR, Kirwan JP: Muscle damage impairs insulin stimulation of IRS-1, PI3-kinase, and Akt-kinase in human skeletal muscle.
Am J Physiol
279
:
E206
–E212,
2000
16.
Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM: IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance.
Science
271
:
665
–668,
1996
17.
Kirwan JP, Krishnan RK, Weaver JA, del Aguila LF, Evans WJ: Human aging is associated with altered TNF-α production during hyperglycemia and hyperinsulinemia.
Am J Physiol
281
:
E1137
–E1143,
2001
18.
Ling PR, Bistrian BR, Mendez B, Istfan NW: Effects of systemic infusions of endotoxin, tumor necrosis factor, and interleukin-1 on glucose metabolism in the rat: relationship to endogenous glucose production and peripheral tissue glucose uptake.
Metabolism
43
:
279
–284,
1994
19.
Clapp JF III, Kiess W: Effects of pregnancy and exercise on concentrations of the metabolic markers tumor necrosis α and leptin.
Am J Obstet Gynecol
182
:
300
–306,
2000
20.
Laham N, Brennecke SP, Bendtzen K, Rice GE: Tumor necrosis factor α during human pregnancy and labor: maternal plasma and amniotic fluid concentration and release from intrauterine tissues.
Eur J Endocrinol
131
:
607
–614,
1994
21.
Beckmann I, Visser W, Struijk PC, van Dooren M, Glavimans J, Wallenburg HCS: Circulating bioactive tumor necrosis factor-α, tumor necrosis factor-α receptors, fibronectin, and tumor necrosis factor-α inducible cell adhesion molecule VCAM-1 in uncomplicated pregnancy.
Am J Obstet Gynecol
177
:
1247
–1252,
1997
22.
Conrad KP, Miles TM, Fairchild Benyo D: Circulating levels of immunoreactive cytokines in women with preeclampsia.
AJRI
40
:
102
–111,
1998
23.
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM: Positional cloning of the mouse obese gene and its human homologue.
Nature
372
:
425
–432,
1994
24.
Muoio DM, Dohm GL, Fiedorek FT Jr, Tapscott EB, Coleman RA: Leptin directly alters lipid partitioning in skeletal muscle.
Diabetes
46
:
1360
–1363,
1997
25.
Shimabukuro M, Koyama K, Chen G, Wang M-Y, Trieu F, Lee Y, Newgard CB, Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of tissues.
Proc Natl Acad Sci U S A
94
:
4637
–4641,
1997
26.
Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM: Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy.
Am J Obstet Gynecol
178
:
1010
–1015,
1998
27.
Catalano PM, Huston LP, Amini SB, Kalhan SC: Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus.
Am J Obstet Gynecol
180
:
903
–906,
1999
28.
Carpenter MW, Coustan DR: Criteria for screening tests for gestational diabetes.
Am J Obstet Gynecol
144
:
768
–773,
1982
29.
Catalano PM, Wong W, Drago NM, Amini SB: Estimating body composition in late gestation: a new hydration constant for body total body water.
Am J Physiol
268
:
E153
–E158,
1995
30.
Kirwan JP, Huston-Presley L, Kalhan SC, Catalano PM: Clinically useful estimates of insulin sensitivity during pregnancy: validations studies in women with normal glucose tolerance and gestational diabetes mellitus.
Diabetes Care
24
:
1602
–1607,
2001
31.
DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance.
Am J Physiol
237
:
E214
–E223,
1979
32.
Hauguel S, Challier JC, Cedard L, Olive G: Metabolism of the human placenta perfused in vitro: glucose transfer and utilization, O2 consumption, lactate and ammonia production.
Pediatr Res
17
:
729
–732,
1983
33.
Tserng KY, Kalhan SC: Calculation of substrate turnover rate in stable isotope tracer studies.
Am J Physiol
245
:
E308
–E311,
1983
34.
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance.
Am J Physiol
280
:
E745
–E751,
2001
35.
Uvena J, Thomas A, Huston L, Highman T, Catalano PM: Umbilical cord leptin and neonatal body composition.
Am J Obstet Gynecol
180
:
S41
,
1999
36.
Coughlan MT, Oliva K, Georgiou HM, Permezel JMH, Rice GE: Glucose-induced release of tumor necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus.
Diabet Med
18
:
921
–927,
2001
37.
Cseh K, Winkler G, Melczer Z, Baranyi E: The role of tumor necrosis factor (TNF)-α resistance in obesity and insulin resistance (Letter).
Diabetologia
43
:
525
,
2000
38.
Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM: Tumor necrosis factor alpha inhibits signaling from the insulin receptor.
Proc Natl Acad Sci U S A
91
:
4854
–4858,
1994
39.
Feinstein R, Kanety H, Papa MZ, Lunefeld B, Karasik A: Tumor necrosis factor-alpha suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates.
J Biol Chem
268
:
26055
–26058,
1993
40.
del Aguila LF, Claffey KP, Kirwan JP: TNF-α impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells.
Am J Physiol
276
:
E849
–E855,
1999
41.
Rui L, Aguirre V, Kim JK, Shulman GI, Lee A, Corbould A, Dunaif A, White MF: Insulin/IGF-1 and TNF-α stimulate phosphorylation of IRS-1 at inhibitory Ser307 via distinct pathways.
J Clin Invest
107
:
181
–189,
2001
42.
Friedman JE, Ishizuka T, Shao J, Huston LP, Highman T, Catalano PM: Impaired glucose transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes.
Diabetes
49
:
1807
–1814,
1999
43.
Shao J, Catalano PM, Yamashita H, Ruyter I, Smith S, Youngren J, Friedman JE: Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycoprotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus (GDM): evidence for increased serine/threonine phosphorylation in pregnancy and GDM.
Diabetes
49
:
603
–610,
2000
44.
Maffei M, Halaas J, Ravussin E, Prately RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone R, Ranganathan S, Kern PA, Friedman JM: Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects.
Nat Med
1
:
1155
–1161,
1995
45.
Knopp RH, Boroush MA, O’Sullivan JB: Lipid metabolism in pregnancy. II. Postheparin lipolytic activity and hypertriglyceridemia in the pregnant rat.
Metabolism
24
:
481
–493,
1975

Address correspondence and reprint requests to John P. Kirwan, Departments of Reproductive Biology and Nutrition, Case Western Reserve University School of Medicine at MetroHealth Medical Center, Bell Greve Bldg., Rm. G-232E, 2500 MetroHealth Dr., Cleveland, OH 44109-1998. E-mail: jpk10@po.cwru.edu.

Received for publication 1 March 2002 and accepted in revised form 3 April 2002.

FFM, fat-free mass; GDM, gestational diabetes mellitus; hCG, human chorionic gonadotropin; HPL, human placental lactogen; IRS, insulin receptor substrate; NGT, normal glucose tolerance; RIA, radioimmunoassay; TNF, tumor necrosis factor.